A study investigates whether semaglutide can reduce cardiovascular risk in overweight and obese patients without diabetes. The study enrolled patients with preexisting cardiovascular disease and a body-mass index of 27 or greater but no history of diabetes. Results show that semaglutide reduces the risk of adverse cardiovascular events in this patient population.
Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown.
In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo
Semaglutide Cardiovascular Risk Overweight Obesity Diabetes Clinical Trial
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetesFindings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.
続きを読む »
Food allergies may be linked to increased cardiovascular death risk, study findsSensitivity to common food allergens such as dairy and peanuts could be an important and previously unappreciated cause of heart disease, new research suggests – and the increased risk for cardiovascular death includes people without obvious food allergies.
続きを読む »
Wegovy slashes risk of heart attacks and strokes in high-risk patients BEFORE weight loss even...Drugmaker Novo Nordisk announced that the treatment reduced the risk of heart attacks and strokes by a fifth in August, illustrating the treatment's benefits beyond weight loss .
続きを読む »
Wegovy slashes risk of heart attacks and strokes in high-risk patients BEFORE weight loss even...Drugmaker Novo Nordisk announced that the treatment reduced the risk of heart attacks and strokes by a fifth in August, illustrating the treatment's benefits beyond weight loss .
続きを読む »
Google will delete MILLIONS of Gmail accounts soon - so, is your account at risk?Starting in December, Google will begin deleting millions of inactive Gmail accounts from its servers as the company warns these unused accounts can be hijacked by hackers for malicious use.
続きを読む »
Storm Debi hits Scotland as torrential rain sparks flood risk and travel alertsThe Met Office has issued a yellow weather warning for rain as Storm Debi arrives in the UK bringing with it wet weather and gale force winds.
続きを読む »